Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus LUPRON DEPOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus LUPRON DEPOT.
FACTREL vs LUPRON DEPOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to reduced gonadal steroidogenesis (testosterone and estrogen). Initial transient stimulation may occur.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
3.75 mg IM monthly for endometriosis; 3.75 mg IM monthly or 11.25 mg IM every 3 months for central precocious puberty; 7.5 mg IM monthly for prostate cancer.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal elimination half-life is approximately 3 hours after single subcutaneous dose; with depot formulations, the apparent half-life is prolonged due to slow release (e.g., 1-month depot: 30 days).
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Primarily renal (90% as unchanged drug and metabolites); biliary/fecal elimination is minimal.
Category C
Category C
GnRH Agonist
GnRH Agonist